Avadel CNS v. Jazz Pharmaceuticals: Infringement Suit Dismissed Without Prejudice in 9 Days
Avadel CNS Pharmaceuticals filed an infringement action against Jazz Pharmaceuticals in the District of Delaware over US12186298B2, a patent connected to LUMRYZ® and XYWAV®. The case was voluntarily dismissed without prejudice just 9 days after filing — one of the shortest litigation windows in recent oxybate patent disputes.
A 9-Day Oxybate Patent Dispute That Ended Before It Began
On 7 January 2025, Avadel CNS Pharmaceuticals, LLC filed an infringement action in the Delaware District Court against Jazz Pharmaceuticals, Inc., asserting US12186298B2. The patent relates to formulations connected to LUMRYZ® — Avadel’s once-nightly extended-release sodium oxybate product — placing it squarely in the commercially contested oxybate sleep-disorder market where Jazz’s XYWAV® also competes.
Just nine days later, on 16 January 2025, Avadel and co-plaintiff Flamel Ireland Limited filed a notice of voluntary dismissal without prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i). This mechanism, available before the defendant serves an answer or a motion for summary judgment, requires no court order and leaves the plaintiffs free to refile the same claims at a later date.
The 9-day duration strongly suggests the complaint was filed strategically — potentially to establish a filing date, preserve rights, or apply commercial pressure — rather than to immediately litigate on the merits. The absence of defendant agents on record is consistent with dismissal occurring before Jazz formally appeared. The public record does not disclose whether the parties reached any side agreement, licensing arrangement, or strategic understanding before dismissal.
Filing to Dismissed without Prejudice in 9 days
9-day lifespan — unusually short even for early voluntary dismissals; median patent case lasts 2–3 years
Dismissed without prejudice: what Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): a unilateral exit before the defendant appears
Under FRCP 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order by filing a notice before the defendant serves an answer or motion for summary judgment. The dismissal is self-executing, requires no judicial approval, and carries no merits adjudication. Avadel exercised this right within 9 days — before Jazz had formally appeared on the docket.
No merits rulingWithout prejudice: the right to refile is preserved — but the record is silent on terms
A dismissal ‘without prejudice’ means Avadel is not barred from asserting US12186298B2 against Jazz in a future action. A dismissal ‘with prejudice’ would extinguish those claims permanently. The public filing specifies ‘without prejudice’, preserving Avadel’s litigation optionality. However, the public record does not disclose whether any collateral agreement — such as a standstill, licence, or covenant not to sue — accompanied the dismissal.
Refiling preservedAvadel retains full enforcement rights over US12186298B2
Avadel’s decision to dismiss voluntarily, rather than litigate, does not constitute any admission regarding validity or infringement. The patent remains in force and enforceable. Avadel and co-plaintiff Flamel Ireland Limited can reassert these claims at any time subject to applicable statutes of limitations, giving them continued leverage in the commercial oxybate market.
Patent still liveJazz faces residual uncertainty — the threat has not been resolved
For Jazz Pharmaceuticals, a without-prejudice dismissal provides no definitive clearance. US12186298B2 remains a potential litigation instrument against XYWAV® or future Jazz products. Jazz may consider seeking inter partes review of the patent, pursuing a declaratory judgment action, or negotiating a licence to obtain more durable certainty — though no such steps are indicated on the public record.
No clearance for JazzFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Avadel CNS Pharmaceuticals, LLC | Company | CNS pharmaceutical company — holder of US12186298B2 (LUMRYZ® oxybate formulation)Search in Eureka ↗ |
| Defendant | Jazz Pharmaceuticals, Inc. | Company | Jazz Pharmaceuticals, Inc. — maker of XYWAV®, competing oxybate sleep-disorder therapySearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) expressly, confirming this was a plaintiff-initiated, unilateral exit requiring no judicial order or defendant consent. The phrase ‘all claims… dismissed without prejudice’ is unambiguous: no claim was adjudicated, no patent validity was tested, and Jazz received no formal clearance. The brevity of the proceeding — 9 days — and the absence of any defendant filings on record are consistent with dismissal before Jazz formally appeared, which is the prerequisite for this rule to apply.
US12186298B2 — once-nightly extended-release sodium oxybate formulation
US12186298B2 (application number US18/758081) is the patent asserted in this action, connected to LUMRYZ® — Avadel’s FDA-approved once-nightly extended-release sodium oxybate product indicated for narcolepsy. The patent covers formulation technology designed to enable a single nocturnal dose, differentiating LUMRYZ® from twice-nightly predecessors in the oxybate class. Sodium oxybate is a tightly regulated CNS depressant with a narrow therapeutic window, making formulation IP particularly strategically valuable.
The commercial stakes around this patent are significant. LUMRYZ® competes directly with Jazz Pharmaceuticals’ XYWAV® (mixed salts oxybate) in the narcolepsy treatment market. Avadel’s once-nightly dosing claim is a core commercial differentiator, and IP protecting that profile carries substantial licensing and enforcement value. The involvement of Flamel Ireland Limited as co-plaintiff suggests a technology transfer or licensing relationship underpinning the patent, which competitors and licensees should investigate carefully.
Should your team run an FTO analysis against US12186298B2?
Any company developing, formulating, or commercialising extended-release sodium oxybate — or structurally analogous CNS depressant formulations — should treat US12186298B2 as an active FTO concern. The without-prejudice dismissal of this case means the patent was never invalidated and Avadel retains full enforcement rights. Generic manufacturers, 505(b)(2) applicants, and novel oxybate formulation developers are all potentially within scope.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map claim scope against their product candidates, identify prosecution history estoppel, and surface related Avadel and Flamel family members that may present parallel risks. Given the speed with which this complaint was filed and dismissed, continuous monitoring — not a one-time search — is the appropriate posture for teams operating in the sodium oxybate space.
Run a freedom-to-operate analysis on US12186298B2 to assess your product’s exposure
Run FTO in Eureka →Similar oxybate pharmaceutical patent cases in the District of Delaware
Explore related sodium oxybate and CNS pharmaceutical patent infringement actions filed in the District of Delaware involving Avadel, Jazz, and comparable formulation IP.
What this case signals for the oxybate IP landscape
A 9-day complaint lifecycle in a high-stakes pharma market rarely means the dispute is over — it often means it is just beginning.
Ultra-short filings in pharma can be tactical positioning, not full litigation
When a pharmaceutical patent complaint is filed and voluntarily dismissed within days — before the defendant even appears — it typically signals strategic intent: securing a filing date, testing jurisdictional options, applying commercial pressure, or preserving rights pending negotiations. Teams monitoring Avadel’s IP activity should treat this filing as a live signal, not a closed chapter.
Without-prejudice exits leave XYWAV® exposed to future enforcement action
Jazz Pharmaceuticals obtained no covenant, no invalidity finding, and no licence from this proceeding. US12186298B2 is still enforceable. R&D and regulatory teams at Jazz — and any company working on sodium oxybate formulations — should maintain active FTO monitoring on this patent and related Avadel/Flamel portfolio assets.
Avadel v Jazz — key questions answered
Avadel CNS Pharmaceuticals and Flamel Ireland Limited filed a patent infringement action against Jazz Pharmaceuticals in the Delaware District Court on 7 January 2025, asserting US12186298B2 in connection with LUMRYZ® and XYWAV®. The case was voluntarily dismissed without prejudice nine days later on 16 January 2025 under FRCP Rule 41(a)(1)(A)(i), before Jazz formally appeared on the docket.
A dismissal without prejudice means Avadel’s infringement claims were not adjudicated on the merits and are not permanently barred. Avadel retains the right to refile an action asserting US12186298B2 against Jazz or other parties in the future, subject to applicable statutes of limitations. The patent itself remains in force and enforceable.
The 9-day lifecycle — filed before defendant appears, dismissed unilaterally — is consistent with several strategic motivations: establishing an early filing date in a patent race, preserving litigation rights while negotiations proceed, applying commercial pressure, or testing jurisdictional options. The public record does not disclose whether any side agreement accompanied the dismissal, so the precise motivation remains unconfirmed.
LUMRYZ® is Avadel’s once-nightly extended-release sodium oxybate product approved for narcolepsy. XYWAV® is Jazz Pharmaceuticals’ mixed-salts oxybate product competing in the same therapeutic category. Both products are identified in the patent case, suggesting Avadel alleged that Jazz’s activities in the oxybate space — potentially including XYWAV® — implicated rights under US12186298B2.
No. A without-prejudice voluntary dismissal provides Jazz with no legal clearance. There was no invalidity finding, no non-infringement adjudication, and no covenant not to sue recorded on the public docket. US12186298B2 remains a live enforcement risk for Jazz and any other party operating in the extended-release sodium oxybate formulation space. Jazz may seek IPR or a declaratory judgment to obtain more durable protection.
PatSnap Eureka searches patents and litigation data to answer instantly.